L Millucci, L Ghezzi, G Bernardini,et al. Conformations and biological activities of amyloid beta peptide 25-35[J]. Curr Protein Pept Sci, 2010,11(1):54.
[2]
Limón I D, Díaz A, Mendieta L,et al. Amyloid-beta(25-35) impairs memory and increases NO in the temporal cortex of rats[J]. Neurosci Res, 2009,63(2):129.
[3]
Stepanichev M Y,MoiseevaY V.Studies of the effects of fragment (25-35) of beta am-yloid peptide on the behavior of rats in a radial maze[J]. Neurosci Behav Physiol,1998,28(5):564.
[4]
Stepanichev M Y, Moiseeva Y V, Lazareva N A,et al.Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats[J].Brain Res Bull,2003,61(2):197.
[5]
徐世军,代渊,张荫杰,等.通络醒脑泡腾片对 Aβ海马注射痴呆大鼠 tau 蛋白磷酸化关键调控蛋白 CDK5 和 GSK-3 表达的影响[J].华西药学杂志,2013,28(2):140.
Atkinsons A J, Colburn W A, DeGruttola V G, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Biomarker definition working group[J]. Clin Pharmacol, 2001, 69: 89.
[10]
Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer\'s disease in blood, plasma, and serum[J]. CNS Neurosci Ther, 2009, 15(4): 358.
[11]
Segura-Aguilar J, Paris I, Mu？oz P,et al.Protective and toxic roles of dopamine in Parkinson\'s disease[J].J Neurochem,2014,129(6):898.
[12]
Munoz-Munoz J L, García-Molina F, Varón R, et al.Generation of hydrogen peroxide in the melanin biosynthesis pathway[J].Biochim Biophys Acta,2009,1794(7):1017.
[13]
Barili Paolo, De Carolis Gionni, Zaccheo Damiano, et al. Sensitivity to ageing of limbic dopaminergic system: a review[J]. Mech Ageing Dev,1998,106 (1/2): 57.
[14]
Kemppainen N, Ruottinen H, Nagren K, et al. PETshows that striatal dopamine D1 and D2 receptors are differently affected in AD[J]. Neurology, 2000,55 (2): 205.
[15]
Davis K L, Davis B M, Greenwald B S,et al.Cortisol and Alzheimer\'s disease, I: basal studies[J].Am J Psychiatry,1986,143(3):300.
[16]
Csernansky J G, Dong H, Fagan A M,et al.Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia[J].Am J Psychiatry,2006,163(12):2164.
[17]
Huang C W, Lui C C, Chang W N, et al.Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer\'s disease[J].J Clin Neurosci,2009,16(10):1283.
[18]
Laughlin G A, Barrett-Connor E.Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo Study[J].J Clin Endocrinol Metab, 2000,85(10):3561.
[19]
Doecke J D, Laws S M, Faux N G,et al.Blood-based protein biomarkers for diagnosis of Alzheimer disease[J].Arch Neurol,2012,69(10):1318.
[20]
Cerqueira J J, Mailliet F, Almeida O F, et al. The prefrontal cortex as a key target of the maladaptive response to stress[J]. J Neurosci,2007,27(11):2781.
[21]
Green K N, Billings L M, Roozendaal B, et al. Glucocorticoids increase amyloid-Band tau pathology in a mouse model of Alzheimer\'s disease[J]. J Neurosci,2006,26(35):9047.
[22]
Sotiropoulos I, Catania C, Riedemann T, et al. Glucocorticoids trigger Alzheimer disease-like pathobiochemistry in rat neuronal cells expressing human tau[J]. J Neurochem,2008,107(2):385.
[23]
Workman J L, Chan M Y, Galea L A.Prior high corticosterone exposure reduces activation of immature neurons in the ventral hippocampus in response to spatial and nonspatial memory[J].Hippocampus,2015,25(3):329.
[24]
Jamieson P M,Nyirenda M J,Walker B R,et al. Interactions between oestradiol and glucocortieoid regulatary effects on liver-specific glucocortieoid-inducible genes, possible evidence for a roal ofhepatic betahydroxysteroid dehydrogenase type[J]. J Endocrinol, 1999,l60: 103.
[25]
Lee S, Xu G, Jay T R,et al.Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway[J].J Neurosci,2014,34(37):12538.
[26]
Sanjay W, Pimplikar. Reassessing the amyloid cascade hypothesis of Alzheimer\'s disease[J]. Int J Biochem Cell Biol,2009,41(6): 1261.
[27]
Ruzzin J,Wagman A S,Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles:defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor[J]. Diabetologia,2005,48(10):2119.
[28]
German J P, Wisse B L, Thaler J P, et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes[J]. Diabetes,2010,59(7):1626.
[29]
Costa,Mara,Pensa,et al. Preparation of 3-mercaptolactic acid and S-aminoethylmercaptolactic acid[J]. Prep Biochem,1982, 12(5):417.
